MNPR · Monopar Therapeutics Inc
United States · RS rating 36 · As of 2026-11-03
| Price | 69.89 USD |
|---|---|
| 1-day change | +5.5% |
| RS rating (overall / 1M / 3M / 12M) | 36 / 34 / 13 / 37 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 35 / 20 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -34.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +43.6% |
| Market cap (USD) | $356.3M |